Study on the expression of interferon alpha related genes in hepatitis C infected patients.

A Thesis

Submitted for the Degree of Ph.D. in Science

(Microbiology)

Presented by

Ghada Maher Mahmoud Salum

(B.Sc. Micro. &Chem. Zagazig University, 2004)

(M.Sc. Microbiology, Cairo University, 2011)

Assistant researcher at Microbial Biotechnology Department

National Research Center

Under supervision of

Prof.Dr. Ahmed B. Barakat

Professor of Virology

Microbiology Department, Faculty of Science

Ain Shams University

Prof.Dr. Mostafa K. El-Awady

Proffessor of Molecular Genetics

Microbial Biotechnology Department

National Research Center

Prof.Dr. Noha G. Bader El Din

Proffessor of Medical Biotechnology

Microbial Biotechnology Department

National Research Center

Microbiology Department
Faculty of Science
Ain Shams University

(2016)

ACKNOWLEDGMENT

First and foremost thanks for ALLAH

There are a lot of people I have to thank for giving me the mental strength and support I needed to complete this thesis.

My Mentors and First teachers, ***my parents,*** *deserve more than acknowledging, their keen patience and endless support for every step in my life. They offered what they could and asked none.*

I would like to express my thanks and gratitude to ***Prof. Dr. Ahmed Barakat Barakat,*** *Professor of Virology; Faculty of science; Ain Shams University, for his kind supervision, guidance, encouragement and his continuous help and endless support throughout this work.*

My deepest heartfelt gratefulness is due to ***Prof. Dr. Mostafa Kamel El-Awady,*** *Professor of Molecular Biochemistry, National Research Center, for suggesting the point of this thesis, building up the hypothesis related to the results. Also, I thank him for his kind supervision and endless support and excellent suggestions during this work. Really, it is a great gift from* ***ALLAH*** *to be one of his students.*

My excellent supervisors ***Prof. Dr. Noha Bader El Dín & Dr. Marwa Ibrahim Khalil*** *deserve a very special mention as their support, guidance, encouragement and reassurance were essential during all stages of this thesis. I want to thank them for their bearing with me on the bad days (and on the good days)! Thank you, dr. Noha, Thank you, dr. Marwa.*

I appreciate the support of my very sweet beloved friend ***sally*** *for her never ending moral support, encouragement and prayers.*

Sincere thanks and respect to ***Prof. Dr. Ashraf Tabll*** *president of Microbial Biotechnology Department, National Research Center.*

Thanks and gratitude to ***Dr, Reem El Shennawy,*** *for her continous help. Also essential was the support provided by all members of the laboratory group, past and present, who made daily life in the lab fun and enjoyable and who had to endure my complaining more often than not! Thank you,* ***Dr, Reham, Yasmine, Rehab, Tawfeek, Mai, and Anany.*** *Many thanks to all members of the Biomicrobial technology Department.*

Tremendous love and special gratitude to my parents and my brothers who always stand beside me when I need them and prayed for my success. Undoubtedly, their prayers are an umbrella of protection. My beloved husband ***Mohamed****, I thank him from the depth of my heart for all of his help, caring attitude, moral support and sharing the moments of anxirety. I especially acknowledge the sacrifice of my son* ***Abdulrahman****, and my daughter* ***Hana*** *who suffered because their mother was busy working on her thesis.*

This dissertation has not been previously submitted for any degree at this or at any other university.

Ghada Maher Salum

List of contents

Page

List of Tables……X

List of Figures……XII

List of Abbreviations……XIV

Chapter I: Introduction……1

Chapter II: Review of Literature…….……....5

2.1 Hepatitis C Virus Characteristics…….……...……..**5**

2.1.1 General Background of Hepatitis C Virus…….……..…**5**

2.1.2 Molecular Virology of HCV……...…….…...**6**

2.1.3 HCV Genotypes and Subtypes…..……...…..**9**

2.1.4 Epidemiology of HCV Genotypes Worldwide…..…...…....**10**

2.1.5 HCV in Egypt…..……...……....**11**

2.1.5 Natural History of Hepatitis C Virus……...…….**13**

2.1.5.1 Acute hepatitis C infection……..……..……**13**

2.1.5.2 Chronic HCV infection…..……**14**

2.1.5.3 Cirrhosis and Hepatocellular Carcinoma…….……..**15**

2.2 HCV Liver disease progression……...……**17**

2.2.1 Liver Fibrosis……..……..**16**

2.3 Factors that Promote Progression of Chronic Hepatitis C……...**19**

2.3.1 Viral Factors…….……**19**

2.3.2 Host Factors…….…….**20**

2.4 Human Immune Response against HCV infection…….……..…**22**

2.4.1 Innate Immune response……...……**23**

2.4.1.1 The Interferon Anti-Viral System……..**24**

2.4.1.1.1 Interferon Family of Cytokines……...**26**

2.4.1.1.2 Interferon Signalling Pathway……...…….**28**

2.4.2 Adaptive Immune Responses……..…….**31**

2.4.2.1 Neutralizing Antibodies**…….…….....32**
2.4.2.2 CD4+ T Cells**…….……33**
2.4.2.3 CD8+ T Cells**…….……34**
2.5 What are the mechanisms of HCV Evasion from Immune Response?…….……..…..**35**
2.5.1 Variability of HCV Sequences**……..…….…..36**
2.5.2 Mutations allow T cell evasion**……..…….……..36**
2.5.3 T Cell Inhibitory Receptors**…...……...37**
2.6 Current treatment approaches and limitations**……...……..38**
2.6.1 Predictors of Progression of HCV Infection**……39**
2.6.1.1 Liver Biopsy**…..……40**
2.6.1.1.1 Liver biopsy scoring systems**…..…….....40**
2.6.1.2 Overview of Non-Invasive Markers of Fibrosis**.....45**
2.6.1.3 Genetic markers for liver fibrosis evaluation**…….…….…...44**
2.6.1.3.1 Gene Expression in Liver Biopsy**…….…..46**
2.6.1.3.2 Gene Expression in Blood (PBMCs)**…….....47**
2.6.1.4 Others markers for liver fibrosis evaluation**……..……48**
2.6.1.4.1 C-Caffeine Breath Test (CBT)**……..…..…48**
2.6.1.4.2 Differentially expressed proteins**……....48**
2.7 Overview of the Latest Techniques for Monitoring the Expression of a Panel Disease-Specific Gene**…….……....49**
2.7.1 Microarray**……...…….....50**
2.7.2. Genes Expression profiling by Real Time PCR and RT² Profiler PCR Arrays**……..…….52**
2.7.2.1 Detection Systems**…...……...….53**
2.7.2.1.1 Non-Specific Detection Systems**……..….53**

2.7.2.1.2 Specific Detection Systems……...**54**

2.7.2.1.2.1 Fluorophore-labeled oligonucleotide……**54**

2.7.2.2 Important Definitions in RT²Profiler PCR Arrays…….....**61**

2.7.2.3 Methods for analyzing real-time PCR data……...**64**

Chapter III: Subjects and Methods……...**67**

3.1.1. HCV- Chronically infected patients**...**…….**67**

3.1.2. Healthy subjects…..…….**68**

3.2. Histologic evaluation of Biopsy samples**...**……**68**

3.3 Detection of HCV RNA…….……**69**

3.4 Total Cellular RNA extraction, Purification and Quality checking….……....**69**

3.4.1. Extraction of Total RNA from PBMCs……...**69**

3.4.1.1 Reagents…..……**69**

3.4.1.2 Supplies…….……**70**

3.4.1.3 Procedure…….……..**71**

3.4.2 Quantification of RNA and Quality checking……..**73**

3.4.2.1 Reagents…….……**73**

3.4.2.2 Supplies…….……**73**

3.4.2.3 Procedure……..……**74**

3.5 cDNA synthesis……...**74**

3.5.1 Reagents…….....**74**
3.5.2 Supplies…..……**75**
3.5.3 Procedure…..……**76**

3.5.3.1 Preparation of Genomic DNA Elimination Mix...…….……**76**
3.5.3.2 Preparation of Reverse Transcription Mix……..……...**76**
3.6 RT² Profiler PCR Arrays……..**78**
3.6.1 Reagents…..…….....**78**
3.6.2 Supplies……..……**79**
3.6.3 Procedure……..**80**
3.7 Real Time PCR for RT² q PCR Primer Assay…….……**82**
3.7.1 Reagents…..…….....**83**
3.7.2 Supplies…….……**83**
3.7.3 Procedure…….……**84**
3.8 Data Normalization…..……**85**
3.9 Human MyD88 ELISA…..……..**85**
3.9.1 Reagents…….…….....**85**
3.9.2 Supplies…….……**87**
3.9.3 Procedure…….……**88**
3.9 Pathway-enrichment analysis…...…….....**89**
3.10 Statistical analysis……..……**90**
3.10.1 Clinical data& gene expression…...……...…**90**
3.10.2 Receiver Operating characteristics (ROC) Curves Analysis…….**90**
3.10.3 Correlation Analysis…..……**91**
Chapter V: Results…….…….....**92**
4.1 Sample description…...……**92**
4.2 Quantification of RNA and Quality checking…….....**94**
4.3 PCR Array Data…….……**95**

4.3.1 Type I IFN genes (84 genes) expression pattern**……..95**
4.3.2 Differential expression of 14 IFN pathway genes showing statistically significant dysregulation in HCV-chronic infected patients compared with healthy controls…..**…….99**
4.3.3 HCV-induced hepatic fibrosis is associated with dysregulated 14 type I IFN pathway related genes**……...……105**
4.3.4 Dysregulation of several type I IFN related transcripts in PBMCs of HCV chronically infected patients with late fibrosis compared to those with early fibrosis**……...……...120**
4.4 Validation of PCR Array Data using real-time PCR**…….……123**

4.4.1 The clinical parameters for the selected subjects for validation of the experiments**……...…….123**

4.4.2 HCV-induced hepatic fibrosis is associated with dysregulated TLR7 cascade pathway **……..…….125**
4.4.3 Evaluation of TLR7 Pathway-related genes as biomarkers for discrimination between HCV fibrotic patients (F0-F4) and healthy controls **…….……. …….127**
4.4.4 Diagnostic value of TLR7 mRNA expression when comparing late HCV fibrotic patients (F2-F4) with early fibrotic patients (F0-F1**)……..……...……...131**
4.5 Correlations between the studied variables in HCV patients**…….…….…….……..134**

4.6 HCV- induced hepatic fibrosis is associated with elevated serum level of MyD88 protein**……...…137**
Chapter V: Discussion……...140

Chapter VI: Summary& Conclusion……...……155

Chapter VII: References……...161

Appendix1: Human Type I Interferon Response RT² Profiler™ PCR Array Gene Table (SABiosciences)…….192

الملخص العربى…….203

المستخلص……..….208

List of Tables

Page

Table (A): Ishak Modified HAI…..…….….**42**

Table (B): The Metavir System…..……..**43**

Table (C): Genomic DNA elimination mix….……**76**

Table (D): Reverse-transcription mix……..……**77**

Table (E): Cycling conditions for Rotor Gene cycler……..…**81**

Table (F): Quantitative real time polymerase-chain reaction (qRT-PCR) primer sequences…….……...…….**82**

Table (G): PCR component mix for one reaction…..…….**84**

Table (1): Clinical features of chronic HCV infected patients with early and late liver fibrosis selected for the PCR array experiment….……....**92**

Table (2): Differential gene expression of type I IFN pathway genes in PBMCs of HCV-chronically infected patients compared to control subjects……...……**97**

Table (3): Differential expression of 14 IFN pathway genes…...…**99**

Table (4): Differential expression of type I IFN pathway genes showing statistically significant regulation in HCV-chronic infected patients with late liver fibrosis compared to patients with early liver fibrosis…….……...…….**120**

Table (5): Clinical features of chronic HCV infected patients with early and late liver fibrosis selected for the validation of qRT-PCR experiments**……..…124**

Table (6): Receiver operating characteristic curves (ROC)**…….....128**

Table (7): Receiver operating characteristic curves (ROC)**…….....131**

Table (8): Relationship between the studied transcripts (TLR 7, MyD88, IRF7, NFκB1) in HCV fibrotic patients assessed by Spearman's (nonparametric) & Person´s (parametric) correlation analyses**……..……..……..…..135**

Appendix1: Human Type I Interferon Response RT² Profiler™ PCR Array Gene Table**…… ……..…….……188**

List of Figures

Page

Figure (A): Simplified graph of the configuration of the Hepatitis C virus particle**……..…….8**

Figure (B): Genome organization of Hepatitis C virus**……..9**

Figure (C): The most common HCV genotype for each country worldwide…**…….…….11**

Figure (D): Natural History of Hepatitis C Virus (HCV) Infection (Seef, 2002)**…….……...16**

Figure (E): Hepatitis C virus (HCV) infection and immune response……**…….……29**

Figure (F): Double-stranded DNA-intercalating agents/DNA-binding dyes**……...…….54**

Figure (G): Diagram represents hydrolysis probes**…….…...…..59**

Figure (H): Diagram depicts hybridization probe**……...60**

Figure (I): Single amplification plot clarifies the definitions commonly used in real-time quantitative PCR**…….……63**

Figure (1): Spectral display showing data for measured RNA sample**…….……..…….95**

Figure (2a): Scatter plot representing dysregulation in type I IFN genes in early fibrotic HCV patients**…….……..…..102**

Figure (2b): Scatter plot representing dysregulation in type I IFN genes in late fibrotic HCV patients**……..104**

Figure (3): Diagrammatic representation of the 14 significantly dysregulated genes when comparing their fold regulation in Early (F0-F1) versus Late (F2-F4) fibrosis**…….……..106**

Figure (4): Diagrammatic representation of type I IFN most dysregulated genes in early versus late fibrotic patients**…….....122**

Figure (5): Diagrammatic representation of the expression pattern of TLR7 pathway key related transcripts in early versus late fibrotic patients**…….127**

Figure (6): ROC curve analyses demonstrate the expression pattern of TLR7 pathway key related transcripts in HCV fibrotic patients (F0-F4) compared to healthy controls**…….……...…130**

Figure (7): Receiver operating characteristic (ROC) curves demonstrate the expression pattern of TLR7 pathway key related transcripts in Early fibrotic patients (F0-F1) compared to Late fibrotic patients(F2-F4)**……. ……134**

Figure (8): Scatter plot presenting the results of person's correlation analysis**…….……....136**

Figure (9): Scatter plot presenting the results of person's correlation analysis**…….……....137**

Figure (10): Diagrammatic representation of MyD88 serum expression in early versus late fibrotic patients**…….……..138**

List of Abbreviations

Abbreviation	Full Name
ALT	Alanine amino transferase
a.a	Amino acid
AUROC	Area under the Receiver Operating Curve
bp	Base pair
B2M	Beta-2-Microglobulin
BMI	Body mass index
CARD	Caspase recruitment domain
CTGF	Connective Tissue Growth Factor
cDNA	Complementary DNA
CRS	Cirrhosis risk score
CBT	Caffiene Breath Test
Ct	Threshold Cycle
DAA	Direct Acting Antiviral Agent
EDITA	Ethylene diamine tetra acetic acid
ELISA	Enzyme Linked Immunosorbent Assay
ECM	Extracellular matrix
GGT	Gamma Glutamyl Transferase
GTP	guanosine triphosphate
HAV	Hepatitis AVirus
HAI	Histology activity index
HBV	Hepatitis B Virus
HCC	Hepatocellular Carcinoma
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus